Abits
ABTS
Bakkt Holdings
BKKT
Riot Platforms
RIOT
Canaan
CAN
Hut 8
HUT
US Stock MarketDetailed Quotes
NTLA Intellia Therapeutics
- 12.660
- -0.901-6.64%
Trading Dec 13 14:07 ET
1.29BMarket Cap-2.32P/E (TTM)
13.520High12.472Low1.97MVolume13.520Open13.560Pre Close25.24MTurnover1.96%Turnover RatioLossP/E (Static)101.85MShares34.87052wk High1.34P/B1.27BFloat Cap12.47252wk Low--Dividend TTM100.57MShs Float202.730Historical High--Div YieldTTM7.73%Amplitude9.180Historical Low12.813Avg Price1Lot Size
About Intellia Therapeutics Company
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Company Profile
SymbolNTLA
Company NameIntellia Therapeutics
Listing DateMay 6, 2016
Issue Price18.00
Founded2014
CEODr. John M. Leonard, M.D.
MarketNASDAQ
Employees526
Fiscal Year Ends12-31
Address40 Erie Street,Suite 130
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02139
Phone1-857-285-6200
Websitehttp://www.intelliatx.com
Company Executives
- Name
- Position
- Salary
- Dr. John M. Leonard, M.D.
- Director, President and Chief Executive Officer
- 11.66M
- Edward J. Dulac, III
- Treasurer, Executive Vice President and Chief Financial Officer
- --
- Eliana Clark
- Executive Vice President and Chief Technology Officer
- --
- Dr. David Lebwohl, M.D.
- Executive Vice President and Chief Medical Officer
- 4.26M
- Dr. Laura Sepp-Lorenzino, PhD
- Executive Vice President and Chief Scientific Officer
- 4.19M
- Derek Hicks
- Executive Vice President and Chief Business Officer
- --
- James Basta, J.D.
- Executive Vice President, General Counsel and Corporate Secretary
- 3.99M
- Dr. Frank Verwiel, M.B.A.,M.D.
- Chairman of the Board
- 499.94K
- Dr. Jesse Goodman, M.D.,M.P.H.
- Independent Director
- 449.94K
- Dr. Fred E. Cohen, D.Phil.,F.A.C.P.,M.D.
- Independent Director
- 452.44K
- Muna Bhanji, Ph.
- Independent Director
- 455.25K
- Dr. Georgia Keresty, M.P.H.,PhD
- Independent Director
- 454.94K
- Brian Goff
- Independent Director
- --
- William J. Chase
- Independent Director
- 996.21K
Trending US Stocks
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
